Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia

Haematologica. 2004 Jul;89(7):ECR20.

Authors

Massimo Breccia¹, Maria Rosaria De Cuia, Gianna Maria D'Elia, Biondo Francesca, Franco Mandelli, Giuliana Alimena

Affiliation

¹ Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy. [email protected]

PMID: 15257957

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Benzamides
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / metabolism
Male
Neoplasms, Multiple Primary* / drug therapy
Neoplasms, Multiple Primary* / metabolism
Piperazines / therapeutic use*
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / metabolism
Proto-Oncogene Proteins c-kit / biosynthesis
Pyrimidines / therapeutic use*
Receptors, Platelet-Derived Growth Factor / biosynthesis
Signal Transduction / drug effects
Testis / metabolism
Testosterone / biosynthesis

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Testosterone
Imatinib Mesylate
Proto-Oncogene Proteins c-kit
Receptors, Platelet-Derived Growth Factor